Personalized Dosing Approaches

Personalized dosing approaches integrate patient-specific variables because each can alter drug exposure or response. Age and body size may influence dose requirements, while organ function can affect how the body handles a medicine. Genetics, drug interactions, and measured pharmacokinetic or pharmacodynamic data add further refinement. Considering these factors together helps clinicians select therapy more appropriately than relying on a single characteristic.

Pharmacokinetic measurements describe drug exposure, whereas pharmacodynamic measurements relate exposure to the body’s response. Using both helps distinguish a dose that produces insufficient effect from one that creates excessive exposure or response. Bayesian dosing models can then combine prior dosing information with new patient data to estimate an individual regimen. This makes adjustment responsive to changing clinical information.

Drug interactions can change the exposure or effect expected from a given dose, and genetic differences may contribute to variation in medication response. Their importance depends on the individual patient and the medicine being used. Including these inputs can help explain why a standard dose may not produce the intended balance of effectiveness and safety, supporting more tailored treatment decisions.

Therapeutic drug monitoring uses measured drug concentrations to refine dosing for an individual patient. Clinicians interpret the result alongside the patient’s characteristics, treatment goals, and other available pharmacokinetic or pharmacodynamic information. The dose can then be adjusted as patient data change. This approach is particularly relevant when maintaining an appropriate exposure is important for balancing treatment benefit and adverse drug reactions.

These approaches are especially valuable when medicines have narrow therapeutic windows, meaning the range between useful and harmful exposure is limited. They can also help when age, body size, organ function, genetics, interactions, or response change the expected dose requirement. In such settings, individualized adjustment may support effectiveness while reducing adverse drug reactions and improving medication safety.

Clinicians can assess whether treatment is achieving its intended goal while limiting adverse drug reactions. Measurements of exposure, pharmacokinetics, or pharmacodynamics may provide evidence for further adjustment, particularly as patient data change. At a broader level, these approaches support safer use of medicines and contribute to precision medicine by linking therapeutic decisions to characteristics and responses observed in individual patients.